The global molecular cytogenetics market was valued at USD 817.5 million in 2015. The increasing incidence of congenital & genetic disorders and the subsequent rise in the early disease diagnostics is expected to boost the demand for molecular cytogenetics over the forecast period.
Technological advancements in the cytogenetic techniques, such as the Comparative Genomic Hybridization (CGH) and the Fluorescence in-situ hybridization (FISH) have led to the advent of enhanced, whole genome screening techniques, which include chromosome microarray analysis and multiplex FISH. Apart from determining the presence of chromosomal aberrations for the diagnosis of genetic diseases, these advanced, high-throughput tools aid in identifying novel therapeutic targets, such as oncogenes that are implicated in tumorigenesis thus boosting the molecular cytogenetics market growth.
The advances in molecular cytogenetics, such as the development of diagnostic tools that are highly sensitive and specific coupled with the emergence of rapid testing platforms for the precise characterization of chromosomal aberrations is anticipated to push forward the growth of the molecular cytogenetics market over the forecast period.
According to the data published by the Centers for Disease Control and Prevention in 2013, it has been identified that due to genetic disorders nearly 3,500 sudden and unexpected infant deaths occur every year in the U.S. Owing to such a high mortality rate, molecular diagnostic techniques such as FISH and CGH are expected to witness high penetration.
Current advances in the next generation sequencing technology, which facilitate comprehensive and cost-effective analyses, are expected to serve the industry with significant growth opportunity over the forecast period.
Global molecular cytogenetics market revenue by technology, 2012 - 2022 (USD Million)
The CGH technology segment held the largest share of nearly 53% and is expected to retain its dominant position over the forecast period. The increasing awareness levels pertaining to the CGH techniques in molecular biology is expected to heighten patient acceptance and broaden the application horizon in molecular diagnostics.
Additionally, the characterization of novel diagnostic biomarkers for effective cancer diagnosis in conjunction with the development of high-resolution, genetic testing platforms for the diagnosis and prognosis of constitutional and acquired diseases are some of the pivotal factors in propelling this segment’s growth in the coming years.
Furthermore, the increasing number of applications for the detection of complex chromosomal arrangements through multicolor FISH techniques and SNP-array analysis is anticipated to upsurge the growth over the forecast period.
In 2014, in terms of revenue, cancer was the largest application segment accounting for over 42% of the overall molecular cytogenetics market. Increasing prevalence of lung, breast, and bladder cancers coupled with the increasing demand for high-throughput diagnostic tools is expected to boost the usage rate of the molecular cytogenetic technologies over the forecast period.
The increase in demand for novel diagnostic systems in response to the need for accurate and timely detection of various genetic disorders due to their increasing global prevalence will further trigger research and development initiatives in the molecular diagnostics sector.
Implementation of routine banded karyotyping analysis for the detection of chromosomal abnormalities and the advancements in molecular techniques facilitate precise detection of syndromes in the pediatric population, which is poised to drive the market over the forecast period.
The application of molecular cytogenetic techniques in the field of personalized medicine is projected to expand the therapeutic horizons in delivering enhanced, molecularly guided therapies, and precise monitoring of disease progression; thus, implying further market expansion over the forecast period.
In 2014, North America emerged as the largest with a share of nearly 46% in the global molecular cytogenetics market. The region’s large share is attributed to the high prevalence rate of cancer and genetic disorders, especially among the infant population that is susceptible to environmental factors such as teratogens.
The prominent drivers of the market in this region include the implementation of advanced molecular cytogenetic techniques, such as FISH and array-comparative genomic hybridization (array-CGH) for early as well as timely detection of diseases, which in turn helps to reduce the high mortality rate and the severe consequences associated with genetic disorders.
Furthermore, there has been an increase in funding through social organizations such as the Leukemia & Lymphoma Society, which is currently funding nearly 300 research programs involved in the development of novel techniques used inthe diagnosisof leukemia and cancer diseases. It is estimated that these novel techniques would further enhance the existent technologies and catapult the market growth.
The Asia pacific molecular cytogenetics market is expected to witness lucrative growth over the forecast period. Europe, followed by Asia Pacific is expected to register the highest increase in the revenue share during the forecast period. Increasing adoption of FISH-based tests for the diagnosis of breast cancer coupled with the increasing prevalence of breast cancer cases is expected to positively influence the growth of FISH technology in the European market.
The Asia Pacific market is mainly driven by the rapidly growing geriatric population base, the increasing cases of chronic diseases and an upward trend in lifestyle diseases. The increasing prevalence of dengue presents a lucrative growth opportunity to the FISH technology pertaining to the detection of potential agents in these disease through various probe assays.
Affymetrix, Inc., Agilent Technologies, Inc., Illumina, Inc., Abbott Laboratories, Bio-Rad Laboratories, Inc., Applied Spectral Imaging, Inc., and Thermo Fisher Scientific (Life Technologies), Inc. are some major players operating in the molecular cytogenetics market. These players develop an array of technologically advanced diagnostic tools, which cater to the needs of numerous diagnostic applications, such as in the diagnosis of cancer and genetic disorders.
Key business strategies adopted by these players include collaborations with research organizations andhospitals to enhance the quality of their existing productsfor subsequent commercializationof these products in an effective manner.One notable instance is the Affymetrix, Inc. collaboration with MTI/EG, a personal genome services provider with an aim to improve the quality of life of patients suffering from genetic disorders.
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.